Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. , the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
~1 min read
Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2. , the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).